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anastrozole was compared with tamoxifen, anastrozole was more effective and costly 
than tamoxifen costing additional KRW 22,461,689 per QALY. Letrozole showed 
similar incremental cost of KRW 21,004,142 per QALY. In the node negative group, 
anastrozole was the most cost-effective with incremental cost of KRW 19,717,770 per 
QALY, while letrozole was the most cost-effective with incremental cost of KRW 
8,150,512 per QALY in node positive group. Sensitive analysis showed that these 
results were robust. CONCLUSIONS: Subgroup analysis clearly demonstrated which 
treatment was superior among aromatase inhibitors. Such a demonstration was not 
conﬁ rmative in the cases of overall population. The implication of this study is that 
the decision maker should be careful when generalizing the cost-effectiveness results. 
The stratiﬁ ed analysis in this context may help reach a reasonable decision on resource 
allocation. 
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ECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) 
VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) 
IN THE TREATMENT OF ADVANCED GASTRIC CANCER IN CHINA
Chen W
Fudan University, Shanghai, China
OBJECTIVES: The objective of the study was to examine the direct medical cost of 
XELOX (capecitabine plus oxaliplatin) compared to FOLFOX (ﬂ uorouracil/leucovo-
rin plus oxaliplatin) for the treatment of advanced gastric cancer in China. METHODS: 
Since the equal efﬁ cacy was already demonstrated by the published literature and local 
clinical guideline, cost minimization analysis was performed to compare the direct 
medical costs of XELOX and FOLFOX for the treatment of advanced gastric cancer. 
The direct medical costs were associated with the drug costs, drug administration 
costs, hospitalization costs and adverse events management costs. The costs were 
calculated based on a questionnaire survey from a clinical expert panel of 20 gastro-
intestinal surgeons and medical oncologists. RESULTS: According to the result of 
clinical expert panel survey, the median treatment duration of XELOX and FOLFOX 
was six cycles and nine cycles, respectively. The drug cost of XELOX regimen was 
CNY 33,948 (US$4992), higher than FOLFOX by CNY 14,160 (US$2082). However, 
the cost increment of XELOX regimen was offset by the higher drug administration 
cost (deviation CNY 9985), hospitalization cost (deviation CNY 4734) and adverse 
events management cost (deviation CNY 1828) of FOLFOX regimen. As a result, 
XELOX showed a signiﬁ cant overall cost savings of CNY 2386 (US$351) compared 
with FOLFOX. CONCLUSIONS: According to the study, XELOX is cost saving in 
comparison with FOLFOX for the treatment of advanced gastric cancer in China, 
especially in the chemotherapy administration and hospitalization utilization. 
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OBJECTIVES: To estimate the clinical and economic effect of Liquid-Based Cytology 
(LBC) compared with Conventional Papanicolaou Smear (CP) screening program in 
Taiwan. METHODS: A decision analytic model was used to simulate the natural 
history of cervical cancer in Taiwan health-care system. This study adopts a Ministry 
of Health perspective in cost-effectiveness analysis to compare a CP strategy every 
year with eight different screening strategies. These strategies comprise three screening 
tools (CP, LBC with Filter Base Technology, and LBC with Cell Enrichment Technol-
ogy), and three screening intervals (annually, every 3 years, and every 5 years). Out-
comes are life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and 
incremental cost-effectiveness ratios (ICER). Future costs and QALYs were discounted 
at an annual rate of 3%. One-way sensitivity analyses are conducted to assess param-
eter uncertainty. RESULTS: Compared with the current screening strategy (an annual 
CP), LBC with Filter Base Technology and LBC with Cell Enrichment Technology 
strategies every 3 or 5 years are less costly while the QALYs lost are trivial. When 
three times GDP per capita is used as the decision threshold, switching cervical cancer 
screening tools from Pap annually to LBC with Filter Base Technology annually 
strategy or LBC with Cell Enrichment Technology annually strategy are cost-effective, 
with ICER equaling NT$233,000 or NT$272,000 per QALY gained, respectively. 
CONCLUSIONS: Results from this study showed that it may be desirable to adopt 
LBC as primary screening tool and may to extend screening interval annually to every 
3 or 5 years in cervical cancer prevention. 
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OBJECTIVES: Sexually-transmitted Human PapillomaVirus (HPV) is the major cause 
of cervical cancer. For its greatest beneﬁ t, HPV vaccine is recommended for young 
girls before there is a possible exposure to HPV through sexual contacts. To assessing 
the potential beneﬁ ts of HPV vaccination program, it is crucial to collect the compre-
hensive information of infectious status and sexual behavior among adolescents. This 
study aims to implement the simulation technique to overcome the information barrier 
in Taiwan. METHODS: A population-based decision analytic model was established 
to simulate the health histories of 15 birth cohorts till they are aged 12 to 26. In the 
starting-point of simulation, these cohorts are aggregated to form a fully representative 
population in 2009. To capture the potential effects of catch-up vaccination programs, 
we computed the initial distribution of health states among each cohort by Markov 
model with cervical cancer natural history in Taiwanese women. We further validated 
the model by comparing the actual epidemiologic data and simulated results. The 
model was applied to estimate the incremental cost-effectiveness ratio (ICER) of 
the different vaccination programs from the perspective of health care. RESULTS: The 
simulated age patterns of HPV prevalence was corresponding to the observed age 
patterns of sexual experience. Based on the model, we found that inclusion of a HPV 
vaccination program for the cohort aged 12 can be considered as cost-effective (ICER 
value 1,010,000 NTD/QALY) comparing with annual Pap smear program only. 
Catch-up vaccination program for the cohorts aged 12–26 can be considered cost-
effective (ICER value 570,000 to 1,300,000 NTD/QALY) comparing with no inter-
vention. Results of sensitivity analysis suggest the robustness of the analysis. 
CONCLUSIONS: We have developed a model incorporating the local health and 
medical conditions. The population-based model is helpful for assessing a complicated 
public policy involved several generations. It provides plentiful information for esti-
mating the beneﬁ ts and budget impact of public policy. 
PCN25
COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL 
AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL 
LUNG CANCER IN KOREA
Kim YG1, Lee EK2
1SookMyung Women’s University, Seoul, South Korea; 2Sookmyung Women’s University, 
Seoul, South Korea
OBJECTIVES: Lung cancer has a high mortality and is associated with a substantial 
ﬁ nancial burden. Cost-effectiveness estimated from foreign studies are usually not 
directly comparable between countries without adapting by applying the appropriate 
national value set. This study was performed to evaluate the cost-effectiveness of 
erlotinib versus docetaxel in patients with advanced non small cell lung cancer(NSCLC) 
who have failed previous chemotherapy in Korea. METHODS: A Markov model 
simulated to access the clinical and economic impact of erlotinib or docetaxel over 2 
years from society perspective. Progression free survival(PFS) and overall survival(OS) 
data were derived from clinical trials, and utility/disutility data were collected in 
published study. Life-year gained(LYG) is projected based on clinical outcomes and 
converted to quality-adjusted life-years (QALYs) by utility weight. Both direct medical 
costs (e.g., drugs, visits, monitoring, etc. ) and nonmedical costs were calculated. Costs 
and outcomes were discounted at an annual rate of 5% and incremental cost-effec-
tiveness ratio (ICER) consists of the difference in cost divided by the difference in 
QALYs. We performed sensitivity analysis to evaluate uncertainty in the results. 
RESULTS: After 2 years follow-up, the total costs per patient was lower with 
erlotinib(11,234,900KRW, 1USD = 1156.53KRW as of February 2010) than with 
docetaxel (12,105,719KRW). More QALY per patient would be obtained with erlo-
tinib than with docetaxel (0.268 and 0.213, respectively). Thus, ICER for erlotinib 
compared to Docetaxel is −15,829,756KRW per QALY. The results of the sensitivity 
analysis showed no signiﬁ cant difference. CONCLUSIONS: This study suggests, with 
its underlying assumptions and data, the use of erlotinib as second- or third-line treat-
ment for advanced NSCLC would not only save costs but also improve outcomes 
compared with docetaxel in Korea. 
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BACKGROUND: CML accounts for 15% of adult leukemia, with incidence ~1 per 
100,000. Imatinib mesylate is an oral medication for chronic phase (CP), accelerated 
phase, or blast crisis phase of CML. For CML patients showing resistance to imatinib, 
dose escalation is a treatment option. Nilotinib is a second generation tyrosine kinase 
inhibitor (TKI), rationally designed to preferentially target BCR-ABL, and has dem-
onstrated efﬁ cacy and safety in patients resistant or intolerant to imatinib. OBJEC-
TIVES: To estimate the total treatment costs and quality-adjusted life-years (QALY) 
gained for patients receiving high-dose imatinib (HDI) ≥600 mg/day because of resis-
tance or nilotinib 800 mg/day using a Markov model to project long-term outcome. 
METHODS: Model parameters were obtained from medical records of patients 
treated with HDI in Taiwan, along with published clinical trial data for HDI and 
nilotinib, and local drug and treatment costs. RESULTS: At the end of July, 2008, 45 
patients who have received imatinib ≥600 mg/day were included in the study and their 
charts were reviewed. During the entire treatment period of HDI and nilotinib, anemia 
was the most common treatment-related adverse event (22.2% vs. 15.6%). The model 
projected longer expected life-years gained by patients receiving nilotinib therapy 
(11.72 years vs. 9.31 years), and patients treated with nilotinib are expected to experi-
ence longer QALY than HDI (9.6 years vs. 7.47 years). Estimated cost per QALY was 
1,189,150 (NTD/year) for nilotinib and 1,169,547 (NTD/year) for HDI. CONCLU-
SIONS: Under the assumption of similar drug price for nilotinib and HD imatinib, 
the beneﬁ t of using nilotinib is obvious for the better clinical outcome achieved in 
terms of lower adverse event rate, better QALY, with acceptable economic impact. 
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The decision of moving therapy from HD imatinib to nilotinib in CML patients with 
resistance to standard dose imatinib is a reasonable option. 
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Pearce AM, Haas M, van Gool K, on behalf of the EMCaP Investigators
University of Technology, Sydney, Ultimo, NSW, Australia
OBJECTIVES: While many new cancer treatments are expensive, their improved side 
effect proﬁ le may reduce overall costs to the health-care system compared to tradi-
tional chemotherapy. The objective of this work was to identify a benchmark 
approach to the estimation of costs for chemotherapy side effects, which could then 
be incorporated into estimates of overall chemotherapy costs. METHODS: A system-
atic review of clinical and economic literature was undertaken using multiple data-
bases and search terms for chemotherapy, adverse events, and cost. Eligible articles 
were reviewed for methods, quality and cost outcomes. Results were combined using 
descriptive techniques to identify best practice methodologies for estimating resource 
use and costs associated with managing chemotherapy side effects. RESULTS: From 
4985 titles, 59 eligible articles were identiﬁ ed. Studies were divided into model based 
analysis (n = 33) and empirical studies (n = 26). The perspectives, approaches, and 
methods for estimating quantities and value of resources consumed were highly vari-
able. These disparate methods contributed to highly divergent estimates of cost when 
speciﬁ c side effects were examined (eg $446 to $17,889 for neutropenia, 2009 AUD). 
A clear benchmark approach to the economic analysis of chemotherapy side effects 
was not available. Thus, general methodological recommendations were made to guide 
development of reliable, valid and transparent estimates of the costs of chemotherapy 
side effects, based on best practice modeling techniques. The recommendations address 
issues such as the use of 1) the health-care system perspective; 2) clinical guidelines 
and patterns of care studies to identify resources; 3) modeling and empirical methods 
to obtain accurate costing information; and 4) appropriate modeling to allow incor-
poration into broader economic evaluations. CONCLUSIONS: These recommenda-
tions provide a framework for developing cost estimates for speciﬁ c adverse events. 
The EMCaP Project will utilize this framework to incorporate estimates of adverse 
event costs into broader economic evaluations of alternative chemotherapy 
protocols. 
CANCER – Patient-Reported Outcomes Studies
PCN28
TRANSLATION AND VALIDATION OF EORTC QLQ–C30 INTO 
INDONESIAN VERSION FOR CANCER PATIENTS IN INDONESIA
Perwitasari DA1, Atthobari J2, Dwiprahasto I2, Hakimi M2, Gelderblom H3, Nortier JWR3, 
Guchelaar HJ3, Kaptein AA3
1Ahmad Dahlan University, Yogyakarta, Indonesia; 2Gadjah Mada University, Yogyakarta, 
Indonesia; 3Leiden University Medical Center, Leiden, The Netherlands
OBJECTIVES: To validate the European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire—C30 (EORTC QLQ-C30) in an Indonesian 
version. The standard procedure of forward-backward translation was adhered to in 
the translation procedures, pilot testing, review, and reliability and construct validity 
evaluation. METHODS: Data were collected from cancer patients in the Oncology 
Department of Dr. Sardjito Hospital, Yogyakarta, Indonesia, who were treated with 
a cisplatin at the dosage ≥50 mg/m2 as monotherapy or in combinations. We used the 
Short Form-36 (SF-36) to assess the construct validity of our translated questionnaire. 
RESULTS: About 85% patients (n = 17) were able to ﬁ ll out the questionnaires by 
themselves and there were no missing responses to the questions in the pilot study. 
One hundred twenty-eight patients with different cancer diagnoses were recruited in 
the validation process from March 2009 to November 2009. The internal consistency 
was above 0.70 for the SF-36 scales physical function, social function, pain, physical 
role, and emotional role; values >0.70 were observed in the Indonesian version of 
EORTC QLQ-C30 scales. Floor and ceiling effects were seen more evidently in the 
physical, social dimensions, pain and fatigue than in single items. Both of the question-
naires showed that different diagnoses were associated with a similar impact of quality 
of life in sensitivity tests. Correlations between Indonesian version of EORTC 
QLQ-C30 and SF-36 dimensions were moderate: between 0.18 and 0.48 for the ﬁ ve 
domains. The discriminant validity between the two questionnaires was acceptable 
(between 0.02–0.47). CONCLUSIONS: The Indonesian version of the EORTC QLQ 
C-30 can be used as a questionnaire to assess quality of life in Indonesian cancer 
patients. 
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OBJECTIVES: Compared with the 3- to 5-year coverage rates of 75% in many 
European countries, the 3-year coverage rate of 51.5% for Pap smear screening in 
Taiwan has not achieved a satisfactory level. Previous studies have showed that 
patients’ preferences were important information for improving the participation rate 
of cancer screening. This study aimed to understand women’s preferences for cervical 
cancer (CC) screening tests with various features. METHODS: Face-to-face patient 
interviews were carried out with 212 women aged 30–55 at the gynecological outpa-
tient clinics in a regional hospital in Taipei, Taiwan, during January and April 2009. 
The participants were asked to rate 12 pairs of hypothetical test scenarios comprised 
of different combinations of six attributes including accuracy of the test, price, screen-
ing administers, place of screening and frequency of screening. The relative importance 
of test attributes was calculated and a cluster analysis was done to identify subgroup 
with differential preferences. RESULTS: Accuracy, price, and place of screening (P < 
0.001) were found to be the most important attributes in determining women’s prefer-
ences. Cluster analysis revealed no signiﬁ cant differences in subgroup of women with 
different health-promoting lifestyles. CONCLUSIONS: The most preferred screening 
programs was “not screening at home,” “high accuracy of test,” and “low price” 
among women residing in a metropolitan city like Taipei. Future direction of study 
on preferences for CC screening should be targeted at women with low utilization of 
Paps smear screening to better inform the decision-makers in designing more effective 
CC prevention program. 
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OBJECTIVES: This study, using DCE method, ﬁ gures out the characteristics of the 
decision-making for lung cancer treatment and investigates the attributes affecting the 
respondents’ choice. Also it ascertains marginal willingness to pay and relative prefer-
ences for lung cancer treatment among the general population of 600 respondents in 
Korea. METHODS: In the survey, the respondents are asked to choose more than one 
discrete choice option, resulting in multiple observations for each individual. For each 
pair-wise comparison of choice set, the respondent will make a choice among three 
alternatives; A, B, or opt out. Thus, the nested-logit model using full maximum likeli-
hood allows us to empirically estimate multi-levels of dependent variables. For the 
robustness check of our empirical results, we try considering the nature of distribution 
of error terms in the utility function in several ways. The survey questionnaire includes 
four attributes associated with lung cancer in Korea (incidence rates, survival rates, 
treatment costs, and monthly insurance premium), socio-economic status, antecedent 
variables, and questions regarding risk averseness and subjective health evaluation. 
RESULTS: The estimates of MWTP between survival rate and monthly insurance 
premium and MTWP between total treatment costs for lung cancer and monthly 
insurance premium, by employing “Hybrid Conditional Fixed Effects Logit Model” 
to ﬁ gure out the existence of heterogeneity of any observed and unobserved compo-
nents, are reﬂ ecting ranges of 261 KRW~286 KRW and 3414 KRW~4538 KRW, 
respectively. CONCLUSIONS: Compared to female counterparts, male respondents 
have higher MWTP of monthly insurance premium for two related attributes. Besides, 
married and younger respondents, with higher income and education have more 
MWTP compared to their respective counterparts. One interesting point is that depen-
dents’ MWTP of survival rate is higher than that of insurance premium payers 
although MTWP of total treatment costs for dependents is signiﬁ cantly lower than 
premium payers’ MWTP. 
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OBJECTIVES: This study, using DCE method, ﬁ gures out the characteristics of the 
decision-making for stomach cancer treatment and investigates the attributes affecting 
the respondents’ choice. Also it ascertains marginal willingness to pay and relative 
preferences for stomach cancer treatment among the general population of 600 respon-
dents in Korea. METHODS: In the survey, the respondents are asked to choose more 
than one discrete choice option, resulting in multiple observations for each individual. 
For each pair-wise comparison of choice set, the respondent will make a choice among 
three alternatives; A, B, or opt out. Thus, the nested-logit model using full maximum 
likelihood allows us to empirically estimate multi-levels of dependent variables. For 
the robustness check of our empirical results, we try considering the nature of distribu-
tion of error terms in the utility function in several ways. The survey questionnaire 
includes four attributes associated with stomach cancer in Korea (incidence rates, 
survival rates in 5 years after treatment, total treatment costs, and monthly insurance 
premium), socio-economic status, antecedent variables, along with questions regarding 
risk averseness and subjective health evaluation. RESULTS: The estimates of MWTP 
between survival rate and monthly insurance premium and MTWP between total 
treatment costs and monthly insurance premium, by employing “Hybrid Conditional 
Fixed Effects Logit Model” to ﬁ gure out the existence of heterogeneity of any observed 
and unobserved components, are reﬂ ecting reasonable range of 176 KRW~194 KRW 
and 5408 KRW~6945 KRW, respectively. CONCLUSIONS: Compared to female 
counterparts, male respondents have higher MWTP of monthly insurance premium 
for two related attributes. Besides, currently married respondents, with higher income, 
and higher educational attainments have more MWTP compared to their respective 
counterparts. One interesting point is that dependents’ MWTP is higher than that of 
insurance premium payers even after controlling for any other variables. 
